NERV Stock Forecast: Minerva Neurosciences, Inc. Price Predictions for 2026-2027

Last close, 19 Nov 2026
$2.12
−2.75% on the day

The median 12-month analyst price target for Minerva Neurosciences, Inc. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 28 of 100 as at 18 Nov 2026 — in the lower half.

Market cap
$107.6M
Ticker Nerd rank
28/ 100
Median analyst target
$10
Analysts covering
3
Revenue$0.0
Operating income−$10.6M
Net income$17.5M
Free cash flow−$13.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−10.9%
1M
−8.6%
YTD
−47.3%
1Y
−50.7%
From 52W high
−73.7%
From 52W low
0.0%
$2.12
$8.07
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Minerva Neurosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 18 Nov 2026
28/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
70
Volatility
64
Momentum
63
Revisions
45
Value
36
Quality
23
Growth
13
Issuance
5

Accruals (70): Reported profit is backed by cash, and the company is not expanding recklessly.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

NERV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on NERV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00$14.00Jan 26Apr 26Jul 26Oct 26NERVHigh $14Median $10Low $7

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
2
Buy
1
Hold
0
Sell
$7
Low
$10
Median
$14
High
Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
14 Aug 2026JefferiesUpgradeBuy$7.50 → $10
15 Apr 2026CitizensInitiatesMarket Outperform$14
12 Mar 2026HC Wainwright & Co.MaintainsNeutral—
6 Nov 2025HC Wainwright & Co.MaintainsNeutral—
26 Feb 2025HC Wainwright & Co.ReiteratesNeutral—
6 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
7 Aug 2024HC Wainwright & Co.MaintainsNeutral—
2 May 2024HC Wainwright & Co.MaintainsNeutral—
27 Feb 2024HC Wainwright & Co.ReiteratesNeutral—
2 Aug 2023HC Wainwright & Co.MaintainsNeutral—
16 May 2023HC Wainwright & Co.ReiteratesNeutral—
2 May 2023HC Wainwright & Co.ReiteratesNeutral—
9 Mar 2023HC Wainwright & Co.ReiteratesNeutral—
10 Nov 2022HC Wainwright & Co.DowngradeNeutral—
17 Oct 2022JMP SecuritiesDowngradeMarket Perform—
4 Mar 2022HC Wainwright & Co.MaintainsBuy$10 → $5.00
8 June 2020HC Wainwright & Co.MaintainsBuy$20 → $10
19 Dec 2019H.C. WainwrightReiteratesBuy—
19 Dec 2019HC Wainwright & Co.ReiteratesBuy$22 → $20
19 Dec 2019JMP SecuritiesMaintainsMarket Outperform$20 → $18

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NERV.

Market Radar

This page is one stock. Monday covers all of them.

NERV appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

NERV vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 19 Nov 2026, Minerva Neurosciences, Inc. returned −50.7% against +9.2% for the S&P 500, dividends included.

NERV vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26NERVS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

NERV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
—
EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
—
Return on assets
−34.7%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Minerva Neurosciences, Inc. has a market value of $107.6M and an enterprise value of $102.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$394.3M.

  • Diluted earnings per share, trailing twelve months: −$28.87.

  • Free cash flow in the twelve months to 30 June 2026: −$26.2M.

  • Shares outstanding: 47.2M.

  • Minerva Neurosciences, Inc. employs 7 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 18 Nov 2026

Data provided by Twelve Data

Peers

NERV and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
NERVMinerva Neurosciences, Inc.$107.6M28
CNTNCanton Strategic Holdings, Inc.$109.0M7
GNLXGenelux Corp.$107.7M14
CMPXCompass Therapeutics, Inc.$110.0M29
FHTXFoghorn Therapeutics, Inc.$104.9M56
CBUSCibus, Inc.$104.4M27
UNCYUnicycive Therapeutics, Inc.$104.2M36

Take a look at NERV’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Minerva Neurosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about NERV

What is the NERV stock price forecast for 2026-2027?

The median 12-month analyst price target for Minerva Neurosciences, Inc. is $10, with estimates ranging from $7 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is NERV stock a buy right now?

Of the 3 analysts covering Minerva Neurosciences, Inc., 2 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Minerva Neurosciences, Inc. 28 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank NERV?

As at 18 Nov 2026, Minerva Neurosciences, Inc. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (70 of 100).

Will NERV stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts is $10, and Ticker Nerd's factor model ranks Minerva Neurosciences, Inc. 28 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the NERV stock forecast for 2030?

No analyst covering Minerva Neurosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NERV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $14 over the next 12 months.

How has NERV stock performed over the past year?

Minerva Neurosciences, Inc. returned -50.7% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Minerva Neurosciences, Inc. do?

Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant.

Company

About Minerva Neurosciences, Inc.

Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant. The company’s work is concentrated on advancing proprietary medicines through clinical development and regulatory pathways, with an emphasis on conditions where treatment options remain limited. Minerva Neurosciences serves a specialized role in the biopharmaceutical market by targeting neuropsychiatric and neurological diseases that affect patients, clinicians, and healthcare systems worldwide. Headquartered in Burlington, Massachusetts, Minerva Neurosciences operates as a research-driven company whose primary business is the development and commercialization of product candidates for complex brain and nervous system disorders.

CEO Dr. Remy Luthringer Ph.D. · 7 employees · United States · https://www.minervaneurosciences.com